Literature DB >> 11230483

Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance.

P G Gobbi1, M L Ghirardelli, M Solcia, G Di Giulio, F Merli, L Tavecchia, R Bertè, O Davini, A Levis, C Broglia, G C Maffè, F Ilariucci, R Dore, E Ascari.   

Abstract

PURPOSE: To explore a more direct method for evaluating tumor burden (TB) in Hodgkin's disease (HD) and to verify its prognostic importance. PATIENTS AND METHODS: The volume of TB at diagnosis was directly and retrospectively measured in 121 HD patients through images of the lesions recorded by computed tomographic (CT) scan of the thorax, abdomen, and pelvis for all deep sites of involvement and many superficial ones, and by ultrasonography (US) for the remaining superficial lesions.
RESULTS: The TB, which was obtained from the sum of the volumes of all the lesions measured on CT scans and US and normalized to body-surface area (relative TB [rTB]), showed a median value of 102.6 cm(3)/m(2) (range, 2.2 to 582.8). At multivariate analysis for prognostic value, rTB was the parameter that statistically correlated best with time to treatment failure (P = 2.2 x 10(-6)), followed by erythrocyte sedimentation rate (ESR) (P =.0003), and serum fibrinogen (P =.0112). The prognostic discrimination allowed by rTB alone proved to be clearly superior to that obtained with the score of the International Prognostic Factor Project. The rTB was found to be correlated with many clinical staging parameters (bulky disease, number of involved lymph node regions, serum lactate dehydrogenase, ESR, hemoglobin, Karnofsky index), but its predictability from these variables was low (R(2) =.668).
CONCLUSION: Relative TB is emerging as a strong prognostic factor in HD, more powerful than and largely independent of those hitherto known and used. Further studies are needed to confirm these results and exploit their clinical value, particularly the relationship among rTB, drug doses, and response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11230483     DOI: 10.1200/JCO.2001.19.5.1388

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  7 in total

1.  Time to Prepare for Risk Adaptation in Lymphoma by Standardizing Measurement of Metabolic Tumor Burden.

Authors:  Sally F Barrington; Michel Meignan
Journal:  J Nucl Med       Date:  2019-04-06       Impact factor: 10.057

2.  Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma.

Authors:  Salim Kanoun; Cédric Rossi; Alina Berriolo-Riedinger; Inna Dygai-Cochet; Alexandre Cochet; Olivier Humbert; Michel Toubeau; Emmanuelle Ferrant; François Brunotte; René-Olivier Casasnovas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-09       Impact factor: 9.236

3.  Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma.

Authors:  Moo-Kon Song; Joo-Seop Chung; Je-Jung Lee; Shin Young Jeong; Sang-Min Lee; Jun-Shik Hong; Ari Chong; Joon-Ho Moon; Ji-Hyun Kim; Seok-Mo Lee; Seong Jang Kim; Ho-Jin Shin
Journal:  Cancer Sci       Date:  2013-10-23       Impact factor: 6.716

4.  Modeling Tumor Evolutionary Dynamics to Predict Clinical Outcomes for Patients with Metastatic Colorectal Cancer: A Retrospective Analysis.

Authors:  Jiawei Zhou; Yutong Liu; Yubo Zhang; Quefeng Li; Yanguang Cao
Journal:  Cancer Res       Date:  2019-11-01       Impact factor: 12.701

5.  Volume assessment accuracy in computed tomography: a phantom study.

Authors:  Nicolas D Prionas; Shonket Ray; John M Boone
Journal:  J Appl Clin Med Phys       Date:  2010-04-16       Impact factor: 2.102

Review 6.  [18F]FDG-PET/CT in Hodgkin Lymphoma: Current Usefulness and Perspectives.

Authors:  Salim Kanoun; Cedric Rossi; Olivier Casasnovas
Journal:  Cancers (Basel)       Date:  2018-05-18       Impact factor: 6.639

Review 7.  Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine.

Authors:  Kamil A Lipinski; Louise J Barber; Matthew N Davies; Matthew Ashenden; Andrea Sottoriva; Marco Gerlinger
Journal:  Trends Cancer       Date:  2016-01-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.